Get the Stockscreener App
3.95
30.79%
0.93
After Hours:
4.77
0.82
+20.76%
Immunitybio Inc stock is traded at $3.95, with a volume of 71.52M.
It is up +30.79% in the last 24 hours and up +77.93% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$3.02
Open:
$3.14
24h Volume:
71.52M
Relative Volume:
5.56
Market Cap:
$3.89B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-4.0722
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+76.34%
1M Performance:
+77.93%
6M Performance:
+44.16%
1Y Performance:
+65.27%
1-Day Range:
$3.07
$3.99
1-Week Range:
$2.26
$3.99
52-Week Range:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
3.95 | 2.97B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% - Nasdaq
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% - The Motley Fool
ImmunityBio stock soars on strong sales growth and global approvals - Investing.com
ImmunityBio reports 700% annual revenue growth for cancer drug Anktiva By Investing.com - Investing.com Nigeria
IBRX Stock Continues Rally — What’s Driving The Optimism Today? - Stocktwits
ImmunityBio Stock Surges on Saudi Cancer Drug Breakthrough - TipRanks
ImmunityBio: Why I Am Upgrading To A Buy For 2026 (NASDAQ:IBRX) - Seeking Alpha
Why Is ImmunityBio Stock Soaring Today?ImmunityBio (NASDAQ:IBRX) - Benzinga
FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026 - Fierce Pharma
ImmunityBio Gains Momentum: Saudi Approval Fuels Stock Surge - StocksToTrade
ImmunityBio shares hit highest since June, last up 12.6% after co's prelim quarterly revenue exceeds estimates - marketscreener.com
ImmunityBio gains as Anktiva powers over 400% Q4 sales growth - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year - Yahoo Finance
Armistice Capital Acquires Shares in ImmunityBio as EMA Recommends ANKTIVA, Q3 Revenue Jumps 434% - Daily Excelsior
Saudi FDA approves ImmunityBio’s ANKTIVA for bladder cancer treatment By Investing.com - Investing.com Nigeria
Patrick Soon-Shiong’s cancer drug approved by Saudi FDA - NewsNation
ImmunityBio (IBRX) Extends Rally on 8th Day on Strong Clinical Trial Results - Finviz
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval - Stocktwits
ImmunityBio rises after Saudi approval of Anktiva - MSN
Assessing ImmunityBio (IBRX) After Its Recent Share Price Surge and DCF Valuation - simplywall.st
H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment - Insider Monkey
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC - Yahoo
ImmunityBio wins Saudi nod for Anktiva (update) (IBRX:NASDAQ) - Seeking Alpha
Accelerated Saudi approval for ImmunityBio’s Anktiva - The Pharma Letter
ImmunityBio (NASDAQ:IBRX) Shares Gap UpStill a Buy? - MarketBeat
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era - Investing News Network
Why ImmunityBio Stock Is Suddenly Surging Higher - TipRanks
ImmunityBio’s Anktiva lung cancer data; Glaukos’ glaucoma implant sales disappoint - Endpoints News
ImmunityBio (IBRX) Price Target Increased by 10.58% to 11.73 - Nasdaq
Saudi FDA approves ImmunityBio’s ANKTIVA for bladder cancer treatment - TipRanks
ImmunityBio announces results from Anktiva clinical program - Yahoo Finance
ImmunityBio Wins Saudi Approvals for ANKTIVA Cancer Therapies - TipRanks
ImmunityBio stock rises after Saudi FDA approves ANKTIVA for lung cancer By Investing.com - Investing.com Nigeria
ImmunityBio, Inc. Announces Accelerated Approval of ANKTIVA® by Saudi FDA - TradingView — Track All Markets
ImmunityBio stock rises after Saudi FDA approves ANKTIVA for lung cancer - Investing.com
Saudi FDA Grants Accelerated Approval to Immunitybio's Anktiva for Non-Muscle Invasive Bladder Cancer with Carcinoma in-situ - marketscreener.com
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer - The AI Journal
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA - Business Wire
ImmunityBio gets lung cancer boost | ApexOncoClinical Trials news and analysis - Oncology Pipeline
ImmunityBio reports positive ANKTIVA results in lung cancer trials By Investing.com - Investing.com Nigeria
Assessing ImmunityBio (IBRX) Valuation After Positive ANKTIVA Lung Cancer Trial Results - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeHere's Why - MarketBeat
Why ImmunityBio (IBRX) Is Up 21.0% After New ANKTIVA Immune-Restoration Data in NSCLC Patients - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral Capital - MarketBeat
Is ImmunityBio (IBRX) Now Attractive After Recent Share Price Rebound And DCF Reassessment - Yahoo Finance
Advance Immunotherapy 2.0 Presented at USA-Saudi Biotech Alliance Summit - Vax-Before-Travel
Traders Purchase High Volume of Call Options on ImmunityBio (NASDAQ:IBRX) - MarketBeat
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients - Stocktwits
ImmunityBio’s Pivotal Role in Bladder Cancer Treatment Shows Promise - StocksToTrade
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):